News Coverage

Laguna Pharmaceuticals Initiates Phase 3 Study of Vanoxerine in Atrial Fibrillation and Atrial Flutter
Posted Sep 14th

Laguna Pharmaceuticals announced today the initiation of a Phase 3 clinical trial for its lead therapeutic candidate, vanoxerine, for treatment of atrial fibrillation (AF) and atrial flutter (AFL)... More >>

Laguna Pharmaceuticals Completes $30 Million Series B Financing, Appoints Industry Veteran Bob Baltera as CEO
Posted Feb 17th

Laguna Pharmaceuticals, previously known as ChanRx, announced today the completion of a $30 million Series B financing and the appointment of Bob Baltera as chief executive officer. Versant Ventures and Frazier Healthcare led the round, joined by BioMed Ventures and Series A investor Sante Ventures... More >>